Boston Scientific Aktie - Fundamentalanalyse - Dividendenrendite KGVBoston Scientific (ISIN: US1011371077, WKN: 884113) Kursdatum: 19.06.2018 Kurs: 31,920 USD
|Land||Vereinigte Staaten von Amerika|
|Rohdaten nach||US GAAP in Millionen USD|
|Aktiensplits||2003-11-06 - 2.0000/1.0000 | 1998-12-01 - 2.0000/1.0000 ||
|Letztes Bilanz Update||23.02.2018|
|Fundamental Verhältnisse errechnet am: 19.06.2018|
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson\'s disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.